Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Persistent malignant stem cells in del(5q) myelodysplasia in remission.


  • Ramin Tehranchi
  • Petter S Woll
  • Kristina Anderson
  • Natalija Buza-Vidas
  • Takuo Mizukami
  • Adam J Mead
  • Ingbritt Åstrand-Grundström
  • Bodil Strömbeck
  • Andrea Biloglav
  • Helen Ferry
  • Rakesh Singh Dhanda
  • Robert Hast
  • Tobias Rydén
  • Paresh Vyas
  • Gudrun Göhring
  • Brigitte Schlegelberger
  • Bertil Johansson
  • Eva Hellström
  • Alan List
  • Lars Nilsson
  • Sten Eirik W Jacobsen

Summary, in English

BACKGROUND: The in vivo clinical significance of malignant stem cells remains unclear. METHODS: Patients who have the 5q deletion (del[5q]) myelodysplastic syndrome (interstitial deletions involving the long arm of chromosome 5) have complete clinical and cytogenetic remissions in response to lenalidomide treatment, but they often have relapse. To determine whether the persistence of rare but distinct malignant stem cells accounts for such relapses, we examined bone marrow specimens obtained from seven patients with the del(5q) myelodysplastic syndrome who became transfusion-independent while receiving lenalidomide treatment and entered cytogenetic remission. RESULTS: Virtually all CD34+, CD38+ progenitor cells and stem cells that were positive for CD34 and CD90, with undetectable or low CD38 (CD38−/low), had the 5q deletion before treatment. Although lenalidomide efficiently reduced these progenitors in patients in complete remission, a larger fraction of the minor, quiescent, CD34+,CD38-/low, CD90+ del(5q) stem cells as well as functionally defined del(5q) stem cells remained distinctly resistant to lenalidomide. Over time, lenalidomide resistance developed in most of the patients in partial and complete remission, with recurrence or expansion of the del(5q) clone and clinical and cytogenetic progression. CONCLUSIONS: In these patients with the del(5q) myelodysplastic syndrome, we identified rare and phenotypically distinct del(5q) myelodysplastic syndrome stem cells that were also selectively resistant to therapeutic targeting at the time of complete clinical and cytogenetic remission. (Funded by the EuroCancerStemCell Consortium and others.)

Publishing year







New England Journal of Medicine





Document type

Journal article


Massachusetts Medical Society


  • Cell and Molecular Biology
  • Medical Genetics


  • Myelodysplastic Syndromes: genetics
  • Myelodysplastic Syndromes: drug therapy
  • Drug Resistance: genetics
  • Pair 5: genetics
  • Human
  • Chromosomes
  • Antineoplastic Agents: therapeutic use
  • Antineoplastic Agents: pharmacology
  • Thy-1: analysis
  • Antigens
  • CD34: analysis
  • CD38: analysis
  • Thalidomide: pharmacology
  • Thalidomide: therapeutic use
  • Thalidomide: analogs & derivatives
  • Neoplastic Stem Cells: immunology
  • Neoplastic Stem Cells: drug effects
  • Myelodysplastic Syndromes: pathology




  • ISSN: 0028-4793